Soiken Holdings Inc. (2385.T)
JPY 129.0
(-1.53%)
JPY 129.0
(-1.53%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -662.2 Million JPY | -246.55% |
| 2022 | 451.84 Million JPY | -44.2% |
| 2021 | 809.71 Million JPY | 44.06% |
| 2020 | 562.06 Million JPY | -23.18% |
| 2019 | 731.68 Million JPY | 32.2% |
| 2018 | 553.46 Million JPY | 179.56% |
| 2017 | 197.97 Million JPY | 6.12% |
| 2016 | 186.56 Million JPY | 299.43% |
| 2015 | 46.7 Million JPY | 946.33% |
| 2014 | -5.51 Million JPY | -121.21% |
| 2013 | 26.02 Million JPY | -62.58% |
| 2012 | 69.54 Million JPY | 137.77% |
| 2011 | -184.14 Million JPY | 35.39% |
| 2010 | -284.98 Million JPY | 75.12% |
| 2009 | -1.14 Billion JPY | -602.26% |
| 2008 | -163.07 Million JPY | -70.0% |
| 2007 | -95.92 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q4 | -87.67 Million JPY | -1.18% |
| 2023 FY | -662.2 Million JPY | -246.55% |
| 2023 Q1 | -527.09 Million JPY | -1087.85% |
| 2023 Q2 | 39.21 Million JPY | 107.44% |
| 2023 Q3 | -86.64 Million JPY | -320.98% |
| 2022 Q1 | 13.74 Million JPY | -91.87% |
| 2022 FY | 451.84 Million JPY | -44.2% |
| 2022 Q4 | -44.37 Million JPY | -115.46% |
| 2022 Q3 | 287.01 Million JPY | 46.84% |
| 2022 Q2 | 195.46 Million JPY | 1322.48% |
| 2021 Q3 | 225.6 Million JPY | -32.12% |
| 2021 Q2 | 332.35 Million JPY | 302.2% |
| 2021 Q1 | 82.63 Million JPY | 1038.6% |
| 2021 FY | 809.71 Million JPY | 44.06% |
| 2021 Q4 | 169.11 Million JPY | -25.04% |
| 2020 Q2 | 345.54 Million JPY | 698.91% |
| 2020 Q1 | 43.25 Million JPY | -86.8% |
| 2020 Q4 | -8.8 Million JPY | -104.84% |
| 2020 Q3 | 182.07 Million JPY | -47.31% |
| 2020 FY | 562.06 Million JPY | -23.18% |
| 2019 Q4 | 327.56 Million JPY | 22.59% |
| 2019 FY | 731.68 Million JPY | 32.2% |
| 2019 Q1 | -226.98 Million JPY | -255.29% |
| 2019 Q2 | 363.9 Million JPY | 260.32% |
| 2019 Q3 | 267.2 Million JPY | -26.57% |
| 2018 Q4 | 146.16 Million JPY | -49.14% |
| 2018 Q2 | 277.23 Million JPY | 276.21% |
| 2018 FY | 553.46 Million JPY | 179.56% |
| 2018 Q1 | -157.33 Million JPY | -3016.81% |
| 2018 Q3 | 287.4 Million JPY | 3.67% |
| 2017 Q3 | 133.44 Million JPY | -10.04% |
| 2017 Q2 | 148.34 Million JPY | 266.29% |
| 2017 FY | 197.97 Million JPY | 6.12% |
| 2017 Q1 | -89.21 Million JPY | -254.1% |
| 2017 Q4 | 5.39 Million JPY | -95.96% |
| 2016 Q4 | 57.89 Million JPY | -57.19% |
| 2016 Q1 | -62.56 Million JPY | -452.09% |
| 2016 FY | 186.56 Million JPY | 299.43% |
| 2016 Q2 | 56.01 Million JPY | 189.53% |
| 2016 Q3 | 135.22 Million JPY | 141.41% |
| 2015 FY | 46.7 Million JPY | 946.33% |
| 2015 Q4 | 17.77 Million JPY | -71.04% |
| 2015 Q3 | 61.36 Million JPY | 10.57% |
| 2015 Q2 | 55.49 Million JPY | 163.12% |
| 2015 Q1 | -87.91 Million JPY | -210.85% |
| 2014 Q3 | 62.63 Million JPY | -22.15% |
| 2014 FY | -5.51 Million JPY | -121.21% |
| 2014 Q4 | 79.31 Million JPY | 26.62% |
| 2014 Q1 | -227.93 Million JPY | -492.0% |
| 2014 Q2 | 80.46 Million JPY | 135.3% |
| 2013 Q3 | 78 Million JPY | -24.79% |
| 2013 Q1 | -117.19 Million JPY | -101.24% |
| 2013 Q2 | 103.72 Million JPY | 188.5% |
| 2013 Q4 | -38.5 Million JPY | -149.36% |
| 2013 FY | 26.02 Million JPY | -62.58% |
| 2012 Q1 | 66.29 Million JPY | 249.71% |
| 2012 Q3 | 12.95 Million JPY | -73.32% |
| 2012 Q2 | 48.54 Million JPY | -26.78% |
| 2012 FY | 69.54 Million JPY | 137.77% |
| 2012 Q4 | -58.23 Million JPY | -549.71% |
| 2011 FY | -184.14 Million JPY | 35.39% |
| 2011 Q4 | -44.28 Million JPY | -40.45% |
| 2011 Q3 | -31.52 Million JPY | 43.75% |
| 2011 Q1 | -52.28 Million JPY | 3.92% |
| 2011 Q2 | -56.04 Million JPY | -7.2% |
| 2010 Q2 | -58.8 Million JPY | 40.69% |
| 2010 Q3 | -72.62 Million JPY | -23.49% |
| 2010 FY | -284.98 Million JPY | 75.12% |
| 2010 Q4 | -54.41 Million JPY | 25.07% |
| 2010 Q1 | -99.14 Million JPY | 83.99% |
| 2009 Q4 | -619.39 Million JPY | -225.32% |
| 2009 FY | -1.14 Billion JPY | -602.26% |
| 2009 Q1 | -155.34 Million JPY | -570.17% |
| 2009 Q2 | -180.1 Million JPY | -15.94% |
| 2009 Q3 | -190.39 Million JPY | -5.72% |
| 2008 Q4 | 33.04 Million JPY | 124.52% |
| 2008 FY | -163.07 Million JPY | -70.0% |
| 2008 Q2 | 75.56 Million JPY | 155.17% |
| 2008 Q1 | -136.96 Million JPY | 0.0% |
| 2008 Q3 | -134.72 Million JPY | -278.29% |
| 2007 FY | -95.92 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 272.449% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | -25.676% |
| GNI Group Ltd. | 8.09 Billion JPY | 108.181% |
| Linical Co., Ltd. | 338.26 Million JPY | 295.764% |
| Trans Genic Inc. | 4.08 Million JPY | 16310.6% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 53.948% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | 579.319% |
| AnGes, Inc. | -7.43 Billion JPY | 91.097% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 48.592% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 90.794% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | 454.7% |
| NanoCarrier Co., Ltd. | -780 Million JPY | 15.102% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | 42.562% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 45.227% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | 18.489% |
| RaQualia Pharma Inc. | -323.66 Million JPY | -104.597% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 45.722% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 53.434% |
| PeptiDream Inc. | 3.03 Billion JPY | 121.813% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 65.84% |
| Ribomic Inc. | -1.02 Billion JPY | 35.347% |
| SanBio Company Limited | -2.64 Billion JPY | 74.955% |
| Healios K.K. | -3.82 Billion JPY | 82.678% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 43.309% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 55.545% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 53.672% |
| StemRIM | -2.02 Billion JPY | 67.25% |
| CellSource Co., Ltd. | 923.14 Million JPY | 171.734% |
| FunPep Company Limited | -933.41 Million JPY | 29.056% |
| Kringle Pharma, Inc. | -854.15 Million JPY | 22.472% |
| Stella Pharma Corporation | -763.74 Million JPY | 13.296% |
| TMS Co., Ltd. | -960.04 Million JPY | 31.023% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | 41.399% |
| Cuorips Inc. | -632.18 Million JPY | -4.749% |
| K Pharma,Inc. | 260.33 Million JPY | 354.371% |
| Takara Bio Inc. | 1.48 Billion JPY | 144.743% |
| ReproCELL Incorporated | -31.41 Million JPY | -2007.92% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | 2610.437% |
| StemCell Institute Inc. | 310.98 Million JPY | 312.94% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | 562.532% |
| CellSeed Inc. | -846.53 Million JPY | 21.775% |